Switch to:

Biomarin Pharmaceutical Return-on-Tangible-Equity

: 9.36%% (As of Sep. 2019)
View and export this data going back to 1999. Start your Free Trial

Return on tangible equity is calculated as Net Income attributable to Common Stockholders divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Biomarin Pharmaceutical's annualized net income attributable to common stockholders for the quarter that ended in Sep. 2019 was $220 Mil. Biomarin Pharmaceutical's average shareholder tangible equity for the quarter that ended in Sep. 2019 was $2,351 Mil. Therefore, Biomarin Pharmaceutical's annualized return on tangible equity (ROTE) for the quarter that ended in Sep. 2019 was 9.36 %%.

NAS:BMRN' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -35.65   Max: 50.34
Current: -1.86

-35.65
50.34

During the past 13 years, Biomarin Pharmaceutical's highest Return on Tangible Equity (ROTE) was 50.34%. The lowest was -35.65%. And the median was -10.38%.

NAS:BMRN's Return-on-Tangible-Equity is ranked higher than
79% of the 1044 Companies
in the Biotechnology industry.

( Industry Median: -52.65 vs. NAS:BMRN: -1.86 )

Biomarin Pharmaceutical Return-on-Tangible-Equity Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Biomarin Pharmaceutical Annual Data
Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Return-on-Tangible-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.98 -12.11 -35.65 -5.70 -3.53

Biomarin Pharmaceutical Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Return-on-Tangible-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.29 -0.65 -9.97 -6.60 9.36

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Biomarin Pharmaceutical Return-on-Tangible-Equity Distribution

* The bar in red indicates where Biomarin Pharmaceutical's Return-on-Tangible-Equity falls into.



Biomarin Pharmaceutical Return-on-Tangible-Equity Calculation

Biomarin Pharmaceutical's annualized Return on Tangible Equity (ROTE) for the fiscal year that ended in Dec. 2018 is calculated as

ROTE=Net Income attributable to Common Stockholders/( (Total Tangible Equity+Total Tangible Equity)/ 2 )
(A: Dec. 2018 )  (A: Dec. 2017 )(A: Dec. 2018 )
=Net Income attributable to Common Stockholders/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ 2 )
(A: Dec. 2018 )  (A: Dec. 2017 )(A: Dec. 2018 )
=-77.211/( (2094.114+2279.093 )/ 2 )
=-77.211/2186.6035
=-3.53 % %

Biomarin Pharmaceutical's annualized Return on Tangible Equity (ROTE) for the quarter that ended in Sep. 2019 is calculated as

ROTE=Net Income attributable to Common Stockholders/( (Total Tangible Equity+Total Tangible Equity)/ 2 )
(Q: Sep. 2019 )  (Q: Jun. 2019 )(Q: Sep. 2019 )
=Net Income attributable to Common Stockholders/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ 2 )
(Q: Sep. 2019 )  (Q: Jun. 2019 )(Q: Sep. 2019 )
=220.144/( (2287.283+2414.517)/ 2 )
=220.144/2350.9
=9.36 % %

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

In the calculation of annual return on tangible equity, the net income attributable to common stockholders of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income attributable to common stockholders data used here is four times the quarterly (Sep. 2019) net income attributable to common stockholders data. Return on Equity is displayed in the 10-year financial page.


Biomarin Pharmaceutical  (NAS:BMRN) Return-on-Tangible-Equity Explanation

Return on Tangible Equity (ROTE) measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). ROTE shows how well a company uses investment funds to generate earnings growth. ROTEs between 15% and 20% are considered desirable.


Be Aware

Net income attributable to common stockholders is used.

Because a company can increase its return on tangible equity by having more financial leverage, it is important to watch the leverage ratio when investing in high ROTE companies. Like Return-on-Tangible-Asset, ROTE is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROTEs can be extremely high.


Biomarin Pharmaceutical Return-on-Tangible-Equity Related Terms


Biomarin Pharmaceutical Return-on-Tangible-Equity Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)